GlaxoSmithKline second-quarter sales rose 2% over the same period last year. CEO Andrew Witty says it is too early to tally the impact of China’s corruption allegations.
Why India’s Actos ban has even local firms puzzled
An agency bellwether, PHCG is hoping to return to growth after a tame 2012, its CEO said this week.
Business briefs: Roche, Vital Art and Science, Gilead, Sanofi
April 9, 2013
5:08 pm
Roche and Isis pair up for Huntingtons, Vital’s prescription vision app gets approved, FDA approval revives maligned morning sickness drug, Gilead sends hep C therapy to regulators and Sanofi’s emerging market exposure grabs attention.
Success in emerging markets hinges on broad network
Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.
Pharma’s iPad, emerging-markets strategies to get 2nd look in 2013, agency execs predict
December 27, 2012
2:19 pm
From tech shifts to talent, and from emerging markets to engaging with social media, agency execs offer their predictions for what the New Year will bring.
Company news: Capgemini, HealthPrize and Warc International
November 26, 2012
8:24 pm
The amount of revenue pharma leaves on the table due to non-adherence is much more than previously thought, a new study suggests.
A global study of consumer attitudes towards health found evidence for the “empowered consumer” hypothesis, with respondents expressing a greater sense of control over and responsibility for their health.
Merck and GSK are both increasing the number of sales reps operating in China, according to separate presentations given by the two companies. In both cases, added reps in emerging markets are helping to offset significant reductions in US sales forces, company executives said.